Dr Naomi Ling

Research Unit

Metabolic signalling


Post-doctoral Senior Research Officer

Professional Experience

2016 – present   Post-doctoral Senior Research Officer, Metabolic Signalling, SVI
2009 – 2015      Research Officer, Protein chemistry & metabolism, SVI
2009 – 2010      Academic visitor at Botany, University of Melbourne
2008                  PhD, School of Botany, University of Melbourne
2002                  MSc (1st Class Hons), University of Canterbury


2019     Secretary General of Asian Society of Kinesiology (ASK) Managing Council
2014     Hamer Scholarship (Victoria Government)
2003     Melbourne International Research Scholarship (Science Faculty MIRS)
2003     CRC for Bioproducts Scholarship
2002     Research Student Scholarship (Lincoln University, NZ)

Research Interests

My primary research focus is to increase our understanding of regulation of AMPK and mTOR signalling pathways, both master regulators of cell metabolism. Dysregulation of these pathways is strongly implicated in the pathogenesis of metabolic diseases such as Type 2 Diabetes and cancer. My research also investigates signal regulation at the organelle- and subunit-specific levels.   

I am also interested in new drug synergy strategies to activate AMPK in cancers such as non small-cell lung carcinoma. AMPK activity in these cancerous cells is low due to lack of the AMPK activating enzyme LKB1; my work indicates this can be corrected by dual drug treatments that operate independently of LKB1.
These projects are being conducted as ongoing collaborations with researchers from the Australian Catholic University, Flinders University and Korea University.

Selected Publications

  1. Ling, N. X. Y., Kaczmarek, A., Hoque, A., Davie, E., Ngoei, K. R. W., Morrison, K. R., Smiles, W. J., Forte, G. M., Wang, T., Lie, S., Dite, T., Langendorf, C. G., Scott, J. W., Oakhill, J. S., and  Petersen, J. (2020) mTORC1 directly inhibits AMPK by attenuating lysosomal targeting. Nature Metabolism.
  2. Nelson, M. E., Parker, B. L., Burchfield, J. G., Hoffman, N. J., Needham, E. J., Cooke, K. C., Naim, T., Sylow, L., Ling, N. X. Y., Francis, D., Norris, D. M., Chaudhuri, R., Oakhill, J. S., Richter, E. A., Lynch, G.S., Stöckli, J., and James, D. E. (2019) Phosphoproteomics reveals conserved exercise-stimulated signaling and AMPK regulation of store-operated calcium entry. The EMBO Journal.
  3. Lee, H. J., Moon, J., Chung, I-H., Chung, J. H., Park, C., Lee, J. O., Han, J. A., Kang, M. J., Yoo,E. H., Kwak, S-Y., Jo, G., Park, W., Park, J., Kim, K. M., Lim, S., Ngoei, K. R. W., Ling, N. X. Y., Oakhill, J. S., Galic, S., Murray-Segal, L., Kemp, B. E., Mantzoros, C. S., Krauss, R. M., Min-Jeong Shin, M-J., and Kim, H. S. (2019) ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways. FASEB Journal.
  4. Hoque, A., Sivakumaran, P., Bond, S.T., Ling, N. X. Y., Kong, A., Scott, J. W., Bandara, N., Hernánde, D.,  Liu, G-S, Wong, R. C. B., Ryan, M. T.,  Hausenloy, D. J., Kemp, B. E., Oakhill, J. S.,  Drew, B. G., Pébay, A., and Lim, S. Y. (2018) Mitochondrial fission protein Drp1 inhibition promotes cardiac mesodermal differentiation of human pluripotent stem cells. Cell Death Discovery 4: 39. doi: 10.1038/s41420-018-0042-9
  5. Ngoei, K. R. W., Langendorf, C. G., Ling, N. X. Y., Hoque, A., Varghese, S., Michelle A. Camerino, M. A., Walker, S. R., Bozikis, Y. E., Dite, T. A., Ovens, A. J., Smiles, W. J., Jacobs, R., Huang, H., Parker, M. W., Scott, J. W., Rider, M. H., Foitzik, R. C., Kemp, B. E.,  Baell, J. B., and Oakhill, J. S. (2018) Structural Determinants for Small-Molecule Activation of Skeletal Muscle AMPK a2β2γ1 by the Glucose Importagog SC4. Cell Chemical Biology 25, 1 – 10.
  6. Dite, T., Ling, N.X.Y., Scott, J.W., Galic, S., Parker, B.L., Ngoei, K.R.W., O’Brien, M. T., Hoque, A., Kundu, M., Steinberg, G.R., Sakamoto, K., Kemp, B. and Oakhill, J. (2017) The autophagy initiator ULK1 sensitizes AMPK to allosteric drugs. Nature Communication 8:571. DOI: 10.1038/s41467-017-00628-y
  7. O’Brien, M.T., Oakhill, J.S., Ling, N.X.Y., Langendorf, C.G., Hoque, A., Dite, T.A., Means, A.R., kemp, B.E. and Scott, J.W. (2017) Impact of genetic variation on human Camkk2 regulation by Ca2+-Calmodulin and multisite phosphorylation. Scientific Reports, 7, 43264. doi:10.1038/srep43264
  8. Ali, N., Ling, N., Krishnamurthy, S., Oakhill, J.S., Scott, J.W., Stapleton, D.I., Kemp, B.E., SrinivsanAnand, G. and Gooley, P.R. (2016) β-subunit myristoylation functions as an energy sensor by modulating the dynamics of AMP-activated protein kinase. Scientific Reports, 6, 39417. doi: 10.1038/srep39471
  9. Langendorf, C.G., Ngoei, K.R.W., Scott, J.W., Ling, N.X.Y., Issa, S.M.A., Gorman, M.A., Parker, M.W., Sakamoto, K., Oakhill, J.S. and Kemp, B. E. (2016) Structural basis of allosteric and synergistic activation of AMPK by furan-2-phophonic derivative C2 binding. Nature Communications, 7, 10912. doi:10.1038/ncomms10912
  10. Scott, J.W., Galic, S., Graham, K.L., Foitzik, R., Ling, N.X.Y., Dite, T.A., Issa, S.M.A., Langendorf, C.G.,  Weng, Q.P., Thomas H.E., Kay, T.W., Birnberg, N.C., Steinberg, G.R., Kemp, B.E. and Oakhill, J.S. (2015). Inhibition of AMP-activated protein kinase at the allosteric drug-binding site promotes islet insulin release. Chemistry & Biology, 22, 705 – 711.
  11. Scott, J.W., Ling, N., Issa, S.M.A., Dite, T.A., O’Brien, M.T., Chen, Z-P., Galic, S., Langendorf, C.G., Steinberg, G.R., Kemp, B.E. and Oakhill, J.S. (2014). Small Molecule Drug A-769662 and AMP synergistically activate naïve AMPK independent of upstream kinase signaling. Chemistry & Biology, 21, 619 – 627.
  12. Scott, J.W., Oakhill, J.S., Ling, N. X.Y., Langerdorf C.G., Foitzik, R.C., Kemp, B.E. and Issinger O-G (2014). ATP sensitive bi-quinoline activator of the AMP-activated protein kinase. Biochemical and Biophysical Research Communications, 443, 435 – 440.